Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

National Academies Join Call For More Diversity In Trials

Executive Summary

A new report from the National Academies of Sciences, Engineering, and Medicine issued a new report on the urgent need for better representation of underrepresented populations in clinical trials and research.

You may also be interested in...



Accelerated Approval, Clinical Trial Diversity Provisions Left Out Of Senate User Fee Bill

Two of the most prominent features of the House package are not addressed in the Senate measure, which predominantly focuses on cosmetics, dietary supplements and laboratory developed tests. The absence of competing proposals suggests a smooth conference process.

Minute Insight: Abbott Sponsors New Physician Training Program To Diversity Clinical Trial Leadership

The company is partnering with the non-profit organization Women as One and the Global Cardiovascular Clinical Trialists to help train physicians from underrepresented populations to lead clinical trials.

FDA Draft Guidance Calls For Trial Diversity Plans

Many companies have been signaling their commitment to diversity and inclusion in trials, but the new draft guidance spells out how they should address it and what the FDA wants to see.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT145432

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel